Beyond cloud and AI, Alphabet has plenty of opportunities. Its search business remains rock solid; it remains a leader in ...

And if it can be as successful as Moderna's CEO believes it can be, then it may not be unrealistic to expect the healthcare ...

Marvell is buying Lumentum for $115 billion in stock. Here's what shareholders give up, what they get, and whether Marvell ...

Over the past five years, however, the stock is down a mammoth 74%, and C3.ai's recent rally may have more to do with ...

Not Joby Aviation, not Archer Aviation (ACHR-4.11%), but Beta Technologies (BETA-2.53%) gets bragging rights as the first ...

Magna International's flexible manufacturing and cost discipline are protecting margins even as production volumes stay weak.

Intel's post-earnings slide is an opportunity for investors to buy a potential long-term winner at an attractive valuation.

At first glance, Alphabet's results were excellent. Revenue jumped 25% year-over-year to $128 billion, giving Alphabet a half ...

Viking Therapeutics (VKTX +1.56%) received a new buy rating from UBS on Oct. 14, with analyst Joon Lee assigning the stock a ...

Signed leases worth 270 basis points of future rent are already locked in, setting up built-in revenue growth for next year.

Beauty sales surged 8% but margins stumbled in North America, exposing an execution gap management must close.

With its new limited-time sign-up bonus, the Capital one Venture Rewards is as good as it's ever been. Here's what to know.